Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The latest update is out from Pacific Edge Limited ( (PFGTF) ).
Pacific Edge Limited announced that the US Centers for Medicare & Medicaid Services (CMS) has published draft ‘Gapfill’ prices for its Cxbladder Triage Plus test, proposing a price of US$1,018.44. This new pricing, once finalized, will enhance the company’s profitability and operational margins, as it represents a significant increase from the current CMS price of US$760 for existing tests. The company plans to prioritize the migration from Triage to Triage Plus, which is expected to improve clinical outcomes and provide cost savings to the Medicare system by reducing unnecessary procedures.
More about Pacific Edge Limited
Pacific Edge Limited is a cancer diagnostics company specializing in innovative tests for the detection and management of cancer. Its primary product, Cxbladder, is a suite of non-invasive tests that help in the diagnosis and management of bladder cancer, focusing on improving patient outcomes and reducing healthcare costs.
YTD Price Performance: -11.43%
Average Trading Volume: 15,850
Technical Sentiment Signal: Buy
Current Market Cap: $55.06M
See more insights into PFGTF stock on TipRanks’ Stock Analysis page.